Navigation Links
NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting
Date:5/31/2008

NEW YORK (May 29, 2008) -- Leading oncologists and cancer researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center are presenting new basic and clinical research findings at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, May 30 to June 3.

Highlights from the symposium presentations and posters to be made by NewYork-Presbyterian/Weill Cornell physician-scientists include the following:

Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients with metastatic castrate-resistant prostate cancer. [Abstract number: 5140; Poster number: 13H]

Time: Saturday, May 31. 8:00 a.m. 12:00 p.m.
Authors: S. T. Tagawa, M. I. Milowsky, M. J. Morris, S. Vallabhajosula, S. Goldsmith, D. Matulich, J. Kaplan, F. Berger, H. I. Scher, N. H. Bander, D. M. Nanus

Drs. Scott Tagawa, Neil Bander and their colleagues at NewYork-Presbyterian/Weill Cornell will present data from a Phase II clinical trial showing that a monoclonal antibody designated "J591," carrying a payload of a radioactive isotope (177Lu), is both safe and effective in the treatment of late-stage metastatic prostate cancer. The antibody works by targeting only prostate cancer cells anywhere in the body while leaving the healthy cells around them unharmed. Patients in this trial had progressing, hormone-independent, metastatic prostate cancer with rapidly increasing prostate specific antigen (PSA) levels. Following only one dose of the J591 antibody loaded with the maximum radiation dose, PSA levels fell in two-thirds of patients with half of all the patients achieving a significant threshold of at least a 30-percent PSA decline. The 30-percent PSA decline threshold has been shown in two large, independent registration trials to be the best PSA surrogate for survival benefit. Additionally, the clinician-scientists found that none of the patients developed s
'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease
2. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
3. Healthy restaurants help make us fat, says a new Cornell study
4. The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell
5. White House awards Weill Cornells Bruce McCandliss highest honor for early career scientists
6. Weill Cornell receives $2.4 million in grants from Gates Foundation to fight tuberculosis
7. NewYork-Presbyterian/Weill Cornell creates world-class cancer center
8. By color-coding atoms, new Cornell electron microscope promises big advance in materials analysis
9. $50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center
10. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
11. Weill Cornell receives funding to study creation of new elder abuse center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...re/ -- The Generic,Pharmaceutical Association (GP...PhA President and CEO Kathleen Jaeger regarding th...merging Health Care Competition and Consumer Issue...ting this roundtable demonstrates the,growing mom...o safe and,affordable biogenerics sooner rather t...
(Date:11/21/2008)...swire/ -- New research at West Virginia Universit...cco product aimed at young adults is catching on. ...amel Snus - touted as a socially acceptable way to...vels of nicotine. , , "Camel Snus contains ...d Bruce Adkins of the state Division of Tobacco Pr...
(Date:11/21/2008)...rstCall/ -- Today, prescription drugs are the firs...ercent of patients suffering chronic conditions. ...condition account for 96 percent of all prescripti...ts. A proprietary new pharmacy model developed ov...SE: MHS ) significantly reduces critical gaps in...
(Date:11/21/2008)...de survey, 33 physicians credentialed to practice ... Hospital of Dallas were honored by Texas Monthly... , , Each year, the publishers of Texas Mo...urvey more than 38,000 medical professionals acros...l care, which doctor would you choose?" Key Profe...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
... at least 10 percent of genes in the human populat...ces they contain—a finding that alters current// t...cent similar in content and identity. This discov..., by Howard Hughes Medical Institute (HHMI) intern...
... deadly infections in humans and animals have show...om the inside out. Now, two new studies at the// J...d that, combined with specially-packaged anti-canc...pects for cancer eradication have dramatically imp...
...ot amputations is high in India, which has around ...s can be considerably reduced with proper foot car...ost diabetic patients, but special footwear is req...er foot deformities. The Diabetes Research Centre...
... that conducted a study on schizophrenic patients ...nd just as well to the older anti-psychotic drugs....a patients who needed a change in drugs as the tre...ive. They were then grouped and some were put on o...
Other Medicine News:Health News:Genetic Variation: We're More Different than We Thought 2Health News:Genetic Variation: We're More Different than We Thought 3Health News:Germ - Chemo Combo Fights Cancer 2Health News:Germ - Chemo Combo Fights Cancer 3Health News:Old Anti-psychotic Drugs Are Equally Good 2
(Date:11/20/2008)...FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI ) ann...hase 1B,clinical trial of their lead drug candida... at the Society for Integrative Oncology,s Fifth I... Company,s oral presentation was selected,as a to... of the Best of the,SIO Session on November 20, 2...
(Date:11/20/2008)...- Radius Health ("Radius") announced today that it...d institutional financing round, increasing total ... amount raised since the company,s inception to $1... participated in the financing, led by MPM Bio IV ...Wellcome Trust, HealthCare Ventures, Oxford Biosci...
(Date:11/20/2008)...- PAREXEL International Corporation (Nasdaq: PRX...rovider, today announced that it has opened an off... and clinical research capabilities. With the addi... throughout five important biopharmaceutical cente... Brazil, Chile, and Mexico. This expansion further...
(Date:11/19/2008)...osit Science Corporation,researcher, Dan Tinker, ...,Annual Conference in Washington, DC this week in... Boomers. The computerized brain plasticity-based...es that target auditory and,language systems. Th...rovements in cognition by improving speed and accu...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Work Time Predicts Sleep Time 375 1Work Time Predicts Sleep Time 375 2China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference 314 1QUANTEL Intends to Strengthen its Dermatology Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH 372 1QUANTEL Intends to Strengthen its Dermatology Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH 372 2Lettuce leafy greens and E coli 370 1Lettuce leafy greens and E coli 370 2
...IRE)--Jul 2, 2007 - Metabasis Therapeutics,(NASDAQ...,discovery, development and commercialization of n...r diseases by targeting the liver,and liver pathwa...esident of finance and chief financial officer of ...in Emerging Growth Opportunities,Conference at the...
... 27, 2007 (PrimeNewswire via COMTEX News,Network) ..., the,leader in drug delivery for metabolic diseas...d today that it will be making three,poster presen...,Society of Pediatric Endocrinology in Helsinki, F...f=,"http://www.espe2007.org/">www.espe2007.org ). ...
Other Medicine Technology:Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth,Conference and Attend Pacific Growth Equities Conference 2Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology 2Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology 3
Holder for QIAGEN 96-well plates, for use with QIAvac 96;
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;
DNA/RNA preparation in 8-multi channels
...llex Filter Units,Filter units with hydrophobic PT...Fluoropore membrane are ideal for the sterilizing ...ners, and for sterilizing or clarifying organic so...units are available with different outlet connecti...
Medicine Products: